Forest Labs Buying Furiex In Deal Worth $1.5B

Forest Laboratories says it will spend as much as $1.5 million to buy Furiex Pharmaceuticals Inc. in a deal that could give the drug maker one of the broadest product lines for gastrointestinal treatments.

Forest says it will pay about $1.1 billion in cash, or $95 per share, for Morrisville, N.C.-based Furiex. It also will make an additional payment of up to about $360 million based on the development of eluxadoline. That treats the symptoms of a form of irritable bowel syndrome. Furiex plans to submit it to regulators for approval later this year.

Forest also plans to divest royalties Furiex receives on a couple of treatments to Royalty Pharma for about $415 million.

New York-based Forest Laboratories Inc. also is the subject of an acquisition bid by Ireland-based Actavis Plc.

More from

FDA Backs Off Feed Rule Affecting Brewers

California 'Kill Switch' Bill For Smartphones Fails

Judge Accepts Settlement In Sudden Acceleration Suit

Explore more news here.

More in Operations